Commerce Spectrum Management Advisory Committee (CSMAC) Working Group (WG) 3 Phase 2 Study Summary

Mapping Intimacies ◽

10.21236/ada590005 ◽

2013 ◽

Author(s):

Albert W. Merrill ◽

Matthew A. Clark ◽

James Hoffman ◽

Gary L. Gallien ◽

Thomas M. Walsh ◽

...

Keyword(s):

Advisory Committee ◽

Working Group ◽

Spectrum Management ◽

Phase 2 ◽

Phase 2 Study ◽

Management Advisory

Download Full-text

Ataluren in Patients Aged  2 to < 5 Years with Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD): 28-week Results from a Phase 2 Study

10.1055/s-0039-1698256 ◽

2019 ◽

Author(s):

Christian Werner ◽

Cuixia Tian ◽

Robert Kong ◽

Edward O’Mara ◽

Traci Schilling ◽

...

Keyword(s):

Duchenne Muscular Dystrophy ◽

Muscular Dystrophy ◽

Nonsense Mutation ◽

Phase 2 ◽

Download Full-text

NEAR-INFRARED FLUORESCENCE MOLECULAR ENDOSCOPY SHOWS PROMISING RESULTS IN DETECTING DYSPLASTIC ESOPHAGEAL LESIONS USING TOPICALLY ADMINISTERED BEVACIZUMAB-800CW: THE PRELIMINARY RESULTS OF A PHASE 2 STUDY

10.1055/s-0040-1704289 ◽

2020 ◽

Author(s):

RY Gabriëls ◽

WTR Hooghiemstra ◽

I Schmidt ◽

JJH van der Laan ◽

G Kats-Ugurlu ◽

...

Keyword(s):

Near Infrared ◽

Phase 2 ◽

Near Infrared Fluorescence ◽

Preliminary Results ◽

Download Full-text

Topical Cantharidin Revisited: A Phase 2 Study Investigating a Commercially-Viable Formulation of Cantharidin (VP-102) for the Treatment of Molluscum Contagiosum

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.2.supp.98 ◽

2018 ◽

Vol 2 ◽

pp. S103-S104

Author(s):

Anthony Guzman

Keyword(s):

Molluscum Contagiosum ◽

Phase 2 ◽

Abstract not available. Disclosures: None. Copyright 2018 SKIN

Download Full-text

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.11 ◽

2017 ◽

Vol 1 ◽

pp. s12

Author(s):

Andrew Blauvelt ◽

Craig Leonardi ◽

Claus Zachariae ◽

Russel Burge ◽

Terri Ridenour ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 2 ◽

Chronic Plaque Psoriasis ◽

Phase 2 Study ◽

Abstract Not Available

Download Full-text

Efficacy of F17464, a New Preferential D3 Antagonist in a Placebo-controlled Phase 2 Study of Patients With an Acute Exacerbation of Schizophrenia

10.26226/morressier.58a41cf4d462b8028d8930e0 ◽

2017 ◽

Author(s):

Francoise Tonner

Keyword(s):

Acute Exacerbation ◽

Phase 2 ◽

Download Full-text

16 / Axicabtagene Ciloleucel in Patients With Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1

10.26226/morressier.5b3b802db1b87b000eceda9c ◽

2018 ◽

Author(s):

Locke Frederick L.

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Phase 2 ◽

Pivotal Phase ◽

Large B Cell Lymphoma ◽

Phase 2 Study ◽

Download Full-text

A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Case Medical Research ◽

10.31525/ct1-nct03919175 ◽

2019 ◽

Author(s):

Keyword(s):

Follicular Lymphoma ◽

Marginal Zone ◽

Initial Therapy ◽

Marginal Zone Lymphoma ◽

Phase 2 ◽

Download Full-text

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Case Medical Research ◽

10.31525/ct1-nct03911713 ◽

2019 ◽

Author(s):

Keyword(s):

Cystic Fibrosis ◽

Phase 2 ◽

Efficacy And Safety ◽

Download Full-text

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

Case Medical Research ◽

10.31525/ct1-nct03980002 ◽

2019 ◽

Author(s):

Keyword(s):

Phase 2 ◽

Multicenter Phase ◽

Phase 2 Study ◽

Treatment Naïve

Download Full-text

A Phase 2 Study for Dose Determination of SRP-5051, Then Dose Expansion in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Case Medical Research ◽

10.31525/ct1-nct04004065 ◽

2019 ◽

Author(s):

Keyword(s):

Duchenne Muscular Dystrophy ◽

Muscular Dystrophy ◽

Phase 2 ◽

Dose Determination ◽

Download Full-text